Organon, a global healthcare company focused on women’s health, has announced a definitive agreement to acquire Dermavant Sciences Ltd., a Roivant company specialising in immuno-dermatology, in a deal valued at up to $1.2 billion. This acquisition marks a significant step in Organon’s strategy to expand its portfolio, particularly in dermatology, where Dermavant has made strides […]
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to addressing one of the most prevalent neurological disorders worldwide. Organon and Eli Lilly Expand Emgality Agreement Organon, a global healthcare company with a focus on women’s health, and Eli Lilly […]
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible to patients in the United States. This development ensures a seamless continuity of care as HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), similar to Humira. HADLIMA, a tumor […]